ALPL and hypophosphatasia: The recently approved bone-targeted TNSALP enzyme replacement therapy, asfotase alfa, has demonstrated significant improvements in skeletal mineralization, including ribs, resulting in improved respiratory function and survival in life-threatening perinatal and infantile HPP cases28.